Talk:Pharmacoeconomics
| This is the talk page for discussing improvements to the Pharmacoeconomics article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
Stripped down
editI have just removed the majority of the text from this article, which was made up of information about economic evaluation and health economics more generally. It also included many contentious discussion points that weren't directly relevant.
Somebody with specific knowledge in pharmacoeconomics needs to outline its defining features, otherwise there seems to be little reason for this page to exist. It could simply redirect to health economics.
Impact of pharmaceutical innovations
editI have doubts about the sentence in the article that 73 % increase in life expectancy is due to pharmaceutical innovations.It is not referenced. 2405:201:1007:835:358E:503E:77D5:5CBC (talk) 15:19, 20 February 2023 (UTC)
Wiki Education assignment: Research Process and Methodology - FA23 - Sect 202 - Thu
edit
This article was the subject of a Wiki Education Foundation-supported course assignment, between 6 September 2023 and 14 December 2023. Further details are available on the course page. Student editor(s): ChrisMisu (article contribs).
— Assignment last updated by ChrisMisu (talk) 21:08, 21 November 2023 (UTC)